G01N 2333/565
Ifn-beta
Official title: IFN-beta
G01N2333/565 (Ifn-beta) appears on 9 US grants and 27 published applications in this corpus.
Search patents in G01N- Granted patents
- 9
- Published applications
- 27
- Assignees
- 22
- Inventors
- 66
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 2 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 2 | 2 |
| 2016 | 0 | 4 |
| 2017 | 0 | 1 |
| 2018 | 1 | 2 |
| 2019 | 0 | 1 |
| 2020 | 1 | 1 |
| 2021 | 0 | 3 |
| 2022 | 0 | 2 |
| 2023 | 1 | 0 |
| 2024 | 1 | 4 |
| 2025 | 1 | 0 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- IFNβ as a pharmacodynamic marker in VSV-IFNβ-NIS oncolytic therapy6 Oct 2026US 12,754,182 B2Mayo Foundation for Medical Education and Research
- Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer18 Feb 2025US 12,227,577 B2Merck Patent GmbH
- Prophylactic agent, onset-suppressing agent or therapeutic agent for progressive immune demyelinating diseases3 Dec 2024US 12,157,772 B2National Center of Neurology and Psychiatry
- Biomarkers for assessing subjects with multiple sclerosis29 Aug 2023US 11,740,248 B2Oklahoma Medical Research Foundation
- Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy22 Sep 2020US 10,782,290 B2Chugai Seiyaku Kabushiki Kaisha
- Cd11b agonists for treatment of autoimmune disease21 May 2026US 2026/0137662 A1149 Bio, LLC
- Anti-pd1 therapy based on response to ifn-i stimulation26 Dec 2024US 2024/0426810 A1University Health Network
- Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment5 Sep 2024US 2024/0293478 A1Actym Therapeutics, Inc.
- Methods for determining tumor immune status6 Jun 2024US 2024/0180984 A1Duke University
- Adjuvant for vaccine development9 May 2024US 2024/0151711 A1
Most cited
By later US patents
- Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy5US 10,782,290 B2Chugai Seiyaku Kabushiki Kaisha · 2020
- Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer1US 12,227,577 B2Merck Patent GmbH · 2025